Endexx Corporation (OTCMKTS: EDXC) To Unveil Brand Blessedwell All Natural Men’s Grooming Line – FactsAboutCBD

Post Views: 51

BetterLife Pharma Inc (OTCMKTS: BETRF) has announced that it has registered its first patient for the Phase 1 part of Phase 1-2 randomized placebo-controlled in COVID-19 patients. The trial is initiated to test the group’s proprietary inhaled interferon alpha-2b product, AP-003.

Team and trial center are leaders in performing COVID-19 trials in Chile

The team of experts and the center are leaders in performing COVID-19 related clinical trials in Chile. The Chief Executive Officer of BetterLife Pharma Inc, Dr. Ahmad Doroudian, went on record and stated that his team is excited to carry out the trial of AP-003 in patients who are tested positive for the coronavirus. Dr. Doroudian informed that the group has partnered with Escuela de Medicina (School of Medicine) at the Pontificia Universidad Católica de Chile to test its proprietary inhaled interferon Alpha-2b product, AP-003. 

It is learned that the test trials of AP-003 are carried out by Altum Pharmaceuticals Inc, which is a 100% owned subsidy of BetterLife Pharma Inc., in partnership with Pontificia Universidad Católica de Chile. 

Result from oriented and non-invasive treatment like AP-003 to treat COVID-19 is the need of the hour

The Study Director of the IN2COVID trial also serves as Associate Professor and Head of Pediatric Immunology, Allergy, and Rheumatology at the School of Medicine of Pontificia Universidad Católica de Chile, Dr. Arturo Borzutzky, commented on the development. He shared that he is pleased to join hands with Altum Pharmaceuticals Inc to bring the AP-003 to patients who tested positive for the coronavirus. 

Dr. Borzutzky added that there are many reasons for the need to have a result-oriented, easy to implement, and non-invasive treatment, like AP-003, to treat patients diagnosed with coronavirus. Listing out the reasons, he said that one of them is the emergence and rampant spread of the SARS-CoV-2 variant. Another reason, according to him, is the sheer lack of scientific knowledge and medical awareness of the period the vaccines can work to protect an individual against the covid virus. Lastly, Dr. Borzutzky strongly believes that the accurate picture of breakthrough infections that vaccinated patients acquire is unclear. Thus, he reiterates that the need of the hour is result-oriented and non-invasive treatment like AP-003 to treat COVID-19. 

BetterLife Pharma Inc is an upcoming biotechnology company involved in developing and commercializing next-generation psychedelic products used to treat a range of mental disorders.

*Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.

You May Also Like

About the Author: SteveSossin

Welcome! I keep up on all the latest cbd and thc news!